top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


FDA Proposes One Approval for Many Mutations in Personalized Gene Editing
A new FDA draft guidance would let one license cover a personalized gene editor and its patient-specific versions. New mutations could be added with lab data instead of new clinical trials, a path built for cases like KJ Muldoon's.
Oct 29


Prime Medicine Doses First Patient With an In Vivo Prime Editor for Wilson Disease
Prime Medicine has dosed the first patient with PM577a, a one-time prime-editing infusion designed to correct the H1069Q mutation in liver cells and restore copper excretion in Wilson disease. It is the company's first prime editor delivered inside the body.
Oct 10


Cornell Scientists Build a Compact, Non-CRISPR Tool That Inserts Whole Stretches of DNA
Cornell researchers fused two bacterial proteins, TldR and TniQ, into a compact RNA-guided system that inserts large pieces of DNA at a chosen site without a CRISPR-Cas protein. It works only in bacteria so far, but it targets one of gene editing's biggest gaps.
Oct 9


Prime Medicine Wins Arbitration Against Beam, Clearing the Way for Its AATD Prime Editor
An arbitration tribunal confirmed Prime Medicine's rights to PM647, a prime-editing therapy for alpha-1 antitrypsin deficiency, ending a dispute with Beam Therapeutics. Here's the science and what comes next.
Jul 7


FDA Draft Guidance Lets Gene-Editing Developers Build on What's Already Known
A June 2026 FDA draft guidance lets developers of genome-editing therapies reuse prior manufacturing, nonclinical and clinical knowledge. Here's why the platform approach could speed rare-disease cures.
Jun 2


Prime Medicine Seeks FDA Approval for the First Prime-Editing Therapy
Prime Medicine plans to seek FDA approval for a prime-editing treatment for chronic granulomatous disease based on two patients. Here's what prime editing is and why this filing is a test case.
Mar 27


CRISPR Gene-Editing Therapies Make Strides, but Cost and Accessibility Remain Key Challenges
As CRISPR-based therapies edge closer to becoming mainstream, groundbreaking treatments for blood disorders and cancer are making their mark. One of the most exciting developments is Casgevy, a gene-editing therapy that has shown remarkable success in treating sickle-cell disease and β-thalassaemia. Approved in both the UK and US, Casgevy works by reactivating fetal hemoglobin, offering patients a chance at long-term relief with fewer blood transfusions and hospital visits. W
Dec 19, 2024


New Gene-Editing Technique: A Better Alternative to CRISPR for Fixing Cystic Fibrosis Mutation
A team from the Broad Institute of MIT and Harvard, along with Harvard University and the Howard Hughes Medical Institute, has made exciting strides in using a gene-editing tool called prime editing to tackle the mutation responsible for cystic fibrosis in human lung cells. This innovative approach offers a more precise and safer alternative to traditional CRISPR methods, significantly lowering the chances of unintended changes to the genome. Cystic fibrosis is a genetic diso
Sep 10, 2024
bottom of page


